Filing summary
Entity and period: This is TenX Keane Acquisition’s Form 10-K for the fiscal year ended December 31, 2023, signed April 16, 2024. Despite the request metadata, the filing is not a 10-K filed by Citius Oncology, Inc.; it is the SPAC’s annual report and discusses its proposed acquisition of Citius Oncology.
Business context and proposed transaction
TenX is a special purpose acquisition company (SPAC) with no operating business. Its activity through year-end was seeking a business combination, initially focused on Asian targets but excluding businesses based in, located in, or principally operating in mainland China, Hong Kong, or Macau.
In October 2023, TenX agreed to combine with Citius Oncology, a wholly owned subsidiary of Citius Pharmaceuticals. Under the announced terms, Citius Pharma would receive 67.5 million shares of the combined company, valued at an implied $675 million, and contribute $10 million in cash; the combined company would also assume 12.6 million existing options. Citius Pharma would continue providing certain management and scientific services under a shared services agreement. The deal remained subject to shareholder approval and other closing conditions; the filing gives no assurance it would close.
Financial results and liquidity
| Metric | 2023 | 2022 |
|---|---|---|
| Operating revenue | None | None |
| Operating expenses | $1.013 million | $138,115 |
| Trust investment income | $3.432 million | $493,020 |
| Net income | $2.419 million | $380,811 |
| Cash used in operating activities | $601,304 | $47,968 |
| Cash used in investing activities | $1.320 million | $67.320 million |
| Cash provided by financing activities | $1.665 million | $67.657 million |
Net income reflected interest earned on trust assets, not operating profitability. Operating costs increased substantially year over year, while trust investment income also rose. Net cash decreased by $256,429 during 2023.
At December 31, 2023, cash outside the trust was $32,746, prepaid expenses were $25,454, and trust investments totaled $72.565 million. Current liabilities were $2.046 million, including $1.320 million in sponsor notes, $344,875 due to a related party, and $375,886 in accrued expenses. There was no long-term debt reported. The 6.6 million public shares were classified as temporary equity, at a redemption value of approximately $10.99 per share; shareholders’ equity was a deficit of $1.988 million. The filing reports no operating or capital lease obligations.
Management and the auditor identified substantial doubt about TenX’s ability to continue as a going concern. The company said it lacked adequate liquidity to sustain operations and might need additional financing. The audit report is unqualified but includes a going-concern explanatory paragraph.
Material developments, outlook, and risks
- Deadline extensions: TenX funded two 2023 extensions with $660,000 each, borrowing from its sponsor. In January 2024, shareholders approved revised extension terms, and Citius Pharma funded a $200,000 extension to April 18, 2024. Further monthly extensions through November 18, 2024 were permitted subject to specified trust deposits; the filing says the sponsor or its affiliates were not obligated to fund them.
- Subsequent redemptions: At the January 17, 2024 meeting, holders redeemed 2,287,923 shares for approximately $24.9 million, based on an approximately $10.90 per-share payment. TenX said the redemption price should instead be $11.02 per share and planned to pay an additional approximately $268,645 in the second quarter of 2024.
- Funding and dilution: The company anticipated $92,000 for transaction and reporting costs and $216,800 for working capital after year-end, and disclosed a sponsor note permitting borrowings up to $300,000. Up to $1.5 million of eligible sponsor or related-party loans could be converted into units at the lender’s option. Additional financing might be needed to complete the proposed transaction.
- Internal controls: Management concluded disclosure controls and internal control over financial reporting were ineffective at year-end due to material weaknesses involving accruals, related-party advances, complex financial instruments, and financial reporting systems. Management said it was assessing resource needs and possible changes. The auditor was not engaged to audit internal controls.
- Related parties and conflicts: TenX paid an affiliate of its sponsor $10,000 monthly for office and administrative services, reimbursed sponsor-related expenses without a stated cap, and had related-party loans and advances. Directors and officers had other business obligations that could affect which acquisition opportunities they present to TenX. The company stated it had not adopted a formal related-party transaction policy.
- Other risks: The filing highlights transaction completion, liquidity, redemption and liquidation risks, possible dilution, and potential regulatory or market risks associated with international targets and PCAOB inspection requirements. TenX reported no material litigation and no cybersecurity threats identified in 2023.
Important facts for investors to verify
- Whether the Citius Oncology business combination closed, on what final terms, and with what shareholder redemptions, financing, and dilution.
- Trust cash remaining after the January 2024 redemptions, the additional redemption payment, and any later extensions or withdrawals.
- Whether additional extension deposits were made and the applicable business-combination deadline.
- How sponsor and related-party notes, advances, and any conversion rights were settled at closing or liquidation.
- Whether management remediated the reported internal-control material weaknesses and whether subsequent filings identify further deficiencies.
- The combined company’s final share count, assumed options, Citius Pharma cash contribution, and ongoing shared-services costs.